InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (67 ops.)
Browse the complete record of transactions filed by Payson Norman, Board Member. Director active across 1 companies, notably Progyny, Inc.. Cumulatively, 72 reports have been logged. Total volume traded: €13m. The latest transaction was disclosed on 22 June 2022 — Cession. Regulator: SEC (Form 4). All data is openly available.
Declarations72 total
€171,3376,618 shares@ €25.88950.0077% mcap1.3% of flow
Common Stock
SEC:0001415889-22-006915:0·
€187,5306,618 shares@ €28.33640.0085% mcap1.4% of flow
Common Stock
SEC:0001415889-22-006415:0·
€180,3726,018 shares@ €29.97210.0081% mcap1.3% of flow
Common Stock
SEC:0001415889-22-005867:0·
€174,7925,518 shares@ €31.67660.0079% mcap1.3% of flow
Common Stock
SEC:0001415889-22-004958:0·
€71,1711,800 shares@ €39.53960.0032% mcap0.5% of flow
Common Stock
SEC:0001415889-22-004226:0·
0225,000 shares0
Common Stock
SEC:0001415889-22-003999:0·
€169,9404,175 shares@ €40.70430.0077% mcap1.3% of flow
Common Stock
SEC:0001179110-22-002321:0·
€18,152450 shares@ €40.33680.0008% mcap0.1% of flow
Common Stock
SEC:0001179110-22-002146:0·
€73,5581,916 shares@ €38.39120.0033% mcap0.5% of flow
Common Stock
SEC:0001104659-22-030786:0·
€173,6845,630 shares@ €30.84970.0078% mcap1.3% of flow
Common Stock
SEC:0001179110-22-001661:0·
€161,4714,556 shares@ €35.44130.0073% mcap1.2% of flow
Common Stock
SEC:0001179110-22-001427:0·
€161,4714,556 shares@ €35.44130.0073% mcap2.6% of flow
Common Stock
SEC:0001179110-22-001427·
€187,4395,328 shares@ €35.180.0085% mcap3.0% of flow
Common Stock
SEC:0001179110-22-001102·
€187,4395,328 shares@ €35.180.0085% mcap1.4% of flow
Common Stock
SEC:0001179110-22-001102:0·
€272,5307,830 shares@ €34.80590.012% mcap4.4% of flow
Common Stock
SEC:0001179110-22-000872·
€272,5307,830 shares@ €34.80590.012% mcap2.0% of flow
Common Stock
SEC:0001179110-22-000872:0·
€86,3832,630 shares@ €32.84520.0039% mcap1.4% of flow
Common Stock
SEC:0001179110-22-000648·
€86,3832,630 shares@ €32.84520.0039% mcap0.6% of flow
Common Stock
SEC:0001179110-22-000648:0·
€131,2703,845 shares@ €34.14050.0059% mcap2.1% of flow
Common Stock
SEC:0001179110-22-000557·
€131,2703,845 shares@ €34.14050.0059% mcap1.0% of flow
Common Stock
SEC:0001179110-22-000557:0·
€112,1982,801 shares@ €40.05640.0051% mcap1.8% of flow
Common Stock
SEC:0001179110-22-000511·
€112,1982,801 shares@ €40.05640.0051% mcap0.8% of flow
Common Stock
SEC:0001179110-22-000511:0·
€140,2873,430 shares@ €40.900.0063% mcap2.3% of flow
Common Stock
SEC:0001179110-22-000342·
€140,2873,430 shares@ €40.900.0063% mcap1.0% of flow
Common Stock
SEC:0001179110-22-000342:0·
€133,0862,920 shares@ €45.57760.0060% mcap2.2% of flow
Common Stock
SEC:0001179110-22-000018·
25 of 72 declarations
About Payson Norman
Norman C. Payson, M.D. is an independent director of Progyny, Inc., where he has served on the board since December 2016. His career is defined by long-standing leadership in healthcare, with more than three decades of executive experience across managed care, physician engagement, and healthcare services. He co-founded Healthsource and served as its Chief Executive Officer from 1985 to 1997. He later led Oxford Health Plans as CEO from 1998 to 2002, chaired Concentra from 2005 to 2008, and served as Chief Executive Officer of Apria Healthcare Group from 2008 to 2012. ([investors.progyny.com](https://investors.progyny.com/board-member/norm-payson/?utm_source=openai)) At Progyny, Payson contributes deep board-level perspective on healthcare delivery, provider alignment, and growth-stage governance. Progyny describes him as a seasoned healthcare executive with 30 to 40 years of experience as a CEO or chairman, including for publicly traded healthcare organizations. That background is particularly relevant to Progyny’s employer-focused fertility and family-building benefits platform, where clinical coordination, cost management, and stakeholder engagement are central to the operating model. He also served as a strategic advisor to Evolent Health from 2014 to 2020 and previously sat on that company’s board through 2019, further broadening his expertise in value-based care and healthcare operating models. ([investors.progyny.com](https://investors.progyny.com/board-member/norm-payson/?utm_source=openai)) Beyond corporate roles, he has remained active in nonprofit, academic, and advisory leadership, including service with City of Hope and other health-related boards and advisory groups. Since 1997, he has also served as President and a director of NCP, Inc., his family office, through which he conducts consulting and personal investment activities. Overall, Payson’s profile combines operational leadership, governance experience, and sector specialization, making him a notable healthcare board member in the U.S. public markets. ([investors.progyny.com](https://investors.progyny.com/board-member/norm-payson/?utm_source=openai))
